Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia

被引：30

作者：

Alfayez, Mansour ^{[1
]}

Richard-Carpentier, Guillaume ^{[1
]}

Jabbour, Elias ^{[1
]}

Vishnu, Prakash ^{[2
]}

Naqvi, Kiran ^{[1
]}

Sasaki, Koji ^{[1
]}

Cortes, Jorge ^{[1
]}

Pemmaraju, Naveen ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Mayo Clin, Dept Hematol, Jacksonville, FL 32224 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 187卷 / 04期

关键词：

dasatinib; tyrosine kinase inhibitor; blastic phase CML; treatment-free remission; sudden blastic transformation; MOLECULAR RESPONSE; IMATINIB; CML; DASATINIB; CESSATION;

D O I：

10.1111/bjh.16245

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：543 / 545

页数：3

共 13 条

[1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts [J].

Abboud, Camille ;

Berman, Ellin ;

Cohen, Adam ;

Cortes, Jorge ;

DeAngelo, Daniel ;

Deininger, Michael ;

Devine, Steven ;

Druker, Brian ;

Fathi, Amir ;

Jabbour, Elias ;

Jagasia, Madan ;

Kantarjian, Hagop ;

Khoury, Jean ;

Laneuville, Pierre ;

Larson, Richard ;

Lipton, Jeffrey ;

Moore, Joseph O. ;

Mughal, Tariq ;

O'Brien, Susan ;

Pinilla-Ibarz, Javier ;

Quintas-Cardama, Alfonso ;

Radich, Jerald ;

Reddy, Vishnu ;

Schiffer, Charles ;

Shah, Neil ;

Shami, Paul ;

Silver, Richard T. ;

Snyder, David ;

Stone, Richard ;

Talpaz, Moshe ;

Tefferi, Ayalew ;

Van Etten, Richard A. ;

Wetzler, Meir ;

Abruzzese, Elisabetta ;

Apperley, Jane ;

Breccia, Massimo ;

Byrne, Jenny ;

Cervantes, Francisco ;

Chelysheva, Ekaterina ;

Clark, R. E. ;

de Lavallade, Hugues ;

Dyagil, Iryna ;

Gambacorti-Passerini, Carlo ;

Goldman, John ;

Haznedaroglu, Ibrahim ;

Hjorth-Hansen, Henrik ;

Holyoake, Tessa ;

Huntly, Brian ;

le Coutre, Philipp ;

Lomaia, Elza .

BLOOD, 2013, 121 (22) :4439-4442

[2] Treatment-free remission with first- and second-generation tyrosine kinase inhibitors [J].

Cortes, Jorge ;

Rea, Delphine ;

Lipton, Jeffrey H. .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) :346-357

[3] Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management [J].

Cortes, Jorge E. ;

Jimenez, Carlos A. ;

Mauro, Michael J. ;

Geyer, Alex ;

Pinilla-Ibarz, Javier ;

Smith, B. Douglas .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (02) :78-82

[4] Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [J].

Cortes, Jorge E. ;

Saglio, Giuseppe ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Mayer, Jiri ;

Boque, Concepcion ;

Shah, Neil P. ;

Chuah, Charles ;

Casanova, Luis ;

Bradley-Garelik, Brigid ;

Manos, George ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2333-U54

[5] Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia [J].

Etienne, Gabriel ;

Guilhot, Joelle ;

Rea, Delphine ;

Rigal-Huguet, Francoise ;

Nicolini, Franck ;

Charbonnier, Aude ;

Guerci-Bresler, Agnes ;

Legros, Laurence ;

Varet, Bruno ;

Gardembas, Martine ;

Dubruille, Viviane ;

Tulliez, Michel ;

Noel, Marie-Pierre ;

Ianotto, Jean-Christophe ;

Villemagne, Bruno ;

Carre, Martin ;

Guilhot, Francois ;

Rousselot, Philippe ;

Mahon, Francois-Xavier .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (03) :298-+

[6] Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV [J].

Hehlmann, Ruediger ;

Mueller, Martin C. ;

Lauseker, Michael ;

Hanfstein, Benjamin ;

Fabarius, Alice ;

Schreiber, Annette ;

Proetel, Ulrike ;

Pletsch, Nadine ;

Pfirrmann, Markus ;

Haferlach, Claudia ;

Schnittger, Susanne ;

Einsele, Hermann ;

Dengler, Jolanta ;

Falge, Christiane ;

Kanz, Lothar ;

Neubauer, Andreas ;

Kneba, Michael ;

Stegelmann, Frank ;

Pfreundschuh, Michael ;

Waller, Cornelius F. ;

Spiekermann, Karsten ;

Baerlocher, Gabriela M. ;

Ehninger, Gerhard ;

Heim, Dominik ;

Heimpel, Hermann ;

Nerl, Christoph ;

Krause, Stefan W. ;

Hossfeld, Dieter K. ;

Kolb, Hans-Jochem ;

Hasford, Joerg ;

Saussele, Susanne ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (05) :415-U51

[7] Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

Jabbour, E ;

Kantarjian, H ;

O'Brien, S ;

Rios, MB ;

Abruzzo, L ;

Verstovsek, S ;

Garcia-Manero, G ;

Cortes, J .

BLOOD, 2006, 107 (02) :480-482

[8] Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib [J].

Jo, Tatsuro ;

Noguchi, Kazuhiro ;

Hayashi, Shizuka ;

Irie, Sadaharu ;

Hayase, Risa ;

Shioya, Haruna ;

Kaneko, Youhei ;

Horio, Kensuke ;

Taguchi, Jun .

ONCOLOGY LETTERS, 2018, 15 (03) :2935-2938

[9]

Nazha A., 2011, BLOOD, V118, P3785

[10] NCCN Guidelines® Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines [J].

Pallera, Arnel ;

Altman, Jessica K. ;

Berman, Ellin ;

Abboud, Camille N. ;

Bhatnagar, Bhavana ;

Curtin, Peter ;

DeAngelo, Daniel J. ;

Gotlib, Jason ;

Hagelstrom, R. Tanner ;

Hobbs, Gabriela ;

Jagasia, Madan ;

Kantarjian, Hagop M. ;

Kropf, Patricia ;

Metheny, Leland ;

Moore, Joseph O. ;

Ontiveros, Evelena ;

Purev, Enkhtsetseg ;

Quiery, Albert ;

Reddy, Vishnu V. B. ;

Rose, Michal G. ;

Shah, Neil P. ;

Smith, B. Douglas ;

Snyder, David S. ;

Sweet, Kendra L. ;

Tibes, Raoul ;

Yang, David T. ;

Gregory, Kristina ;

Sundar, Hema ;

Deininger, Michael ;

Radich, Jerald P. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (12) :1505-1512

← 1 2 →